A Global Pharmaceutical Corporation in Asia

A leading multinational pharmaceutical enterprise sought to identify and acquire high-potential early-stage oncology and metabolic disease compounds developed across research institutions in Asia, but faced significant hurdles in technical due diligence and cross-border IP valuation. The enterprise required specialized external expertise to conduct techno-economic due diligence, evaluate early-stage patent portfolios, and establish risk-mitigated out-licensing and corporate venturing frameworks.

Oxford Oracle executed a comprehensive technology scouting and due diligence campaign. Leveraging deep domain expertise, Oxford Oracle audited over 80 university research pipelines, evaluated preclinical validation data, and structured risk-mitigated licensing option agreements. Oxford Oracle deployed a multidisciplinary advisory team to execute comprehensive technical due diligence, design bespoke commercialisation roadmaps, and establish standardized stage-gate evaluation metrics.

The engagement facilitated the successful optioning and licensing of 4 breakthrough therapeutic candidates, resulting in a $32 million biopharma partnership deal and accelerating two novel compounds into Phase I clinical trials. Furthermore, the engagement established a permanent, scalable operational blueprint, driving long-term strategic alignment, continuous revenue growth, and enhanced institutional reputation across global innovation networks.